Navigation Links
Reaction To ADHD Medication May Be Genetic By Nature

New research points out that the difference in genes might be responsible for the way patients suffering from attention deficit hyperactivity disorder (ADHD) differ in reacting to medications. //

The study, done by the researchers from University of Illinois at Chicago, had found that children with a variant form of a dopamine transporter gene -- a variant known to be associated with ADHD -- responded poorly to one of the most common stimulant medications, methylphenidate. The transporter gene encodes a protein on the nerve cell membrane that helps to clear the neurotransmitter dopamine from the nerve junction.

The researchers had first reported an association of this gene with ADHD 10 years ago. In the new study, they had examined the relationship between the gene and patients' medication response over a four-week period, first on a placebo and then on three increasing dosages of methylphenidate.

The researchers tested 47 children with ADHD between 5 and 16 years old to determine which variant of the dopamine transporter gene they carried. They focused on two specific variants -- called 9R and 10R -- of the transporter gene and evaluated how varying doses of methylphenidate would affect ADHD symptoms, impairment, and stimulant side effects.

The majority of the patients had one or two copies of the 10R variant. Of these children, nearly 60 percent had excellent response to the highest dosage (54 milligrams). In contrast, of the patients with two copies of the 9R variant, none displayed such dramatic improvement.

Results of the current study appear in the July issue of the journal Neuropsychopharmachology.

Source: Newswise
'"/>




Page: 1

Related medicine news :

1. Diet Can Influence Allergic Skin Reactions
2. Influence of diet on allergic Reactions
3. Red Color Causes The Allergic Reaction To Strawberries
4. New Insight Gained For Allergic Reactions
5. Emergency Treatment Found Wanting In Anaphylactic Reactions
6. Cancer Causing Proteins Trigger Abnormal Biochemical Reactions In Cells
7. New Medicare Plan - Mixed Reaction among Pharmacists.
8. Drug Reactions First Present Themselves In The Mouth
9. Eye Drug Macugen Shows Allergic Reactions
10. Gender Difference In Reaction To Cancer
11. Mouse Model Demonstrates Immune System Reaction In Chlamydia Infection
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... choose a modern procedure that achieves results in a fraction of the time ... Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment with ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers of America ... a reputable physician in their area, announces the launch of a new and proprietary ... who are looking for reputable physicians to help them with back or neck pain ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... 2017 , ... Vetoquinol USA® , a world-class developer ... of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. ... level. , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the ... CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet in ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... PARIS , April 20, 2017 ... EyeCET platform, the first non-viral gene expression technology that ... in the eye to address a wide range of ... UK Medicines and Healthcare products Regulatory Agency (MHRA) to ... ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology: